Published: 2022-07-27

The efficacy of intravitreal dexamethasone implant for branch retinal vein occlusion related macular edema

Latika Pandey, Jitender Phogat, Monika Dahiya, Ritesh Verma, Arjun P., V. K. Dhull


Background: To study the efficacy of intravitreal injection of dexamethasone implant on central macular thickness in patients with BRVO.

Methods: A prospective, longitudinal and interventional study was conducted on 30 patients of BRVO presenting to our OPD over a period of one year. Thorough history and detailed ocular examination was done. All cases included in this study received intravitreal injection of dexamethasone implant and were followed up at the first, third and sixth month post-injection to record any change in BCVA, CMT and IOP.

Results: In this study, the mean age of patients was 60.67±7.02 years with a M:F ratio of 1:2. Maximum patients (46.6%) were of 61-70 years age group. A significant change from baseline was observed in BCVA and CMT at 1, 3 and 6 months post injection. BCVA significantly improved at 6th month (0.46±0.20 log MAR) compared to the mean BCVA at 3rd month (0.39±0.15 log MAR) (p<0.001). At the 6th month follow up, the mean CMT (338.33±77.91 µm) (p<0.001) was significantly lower compared to the baseline value (536.23±114.56 µm) (p<0.001) but got significantly increased compared to the mean CMT at third month (p<0.001). IOP values were significantly higher at 1 month (p<0.001) and 3 months (p<0.001) compared to the baseline value. 

Conclusions: Dexamethasone implant 0.7 mg is beneficial in the improvement of BCVA and treatment of macular edema due to BRVO. However, any beneficial effect on visual acuity and macular edema on OCT seen initially, starts weaning off after 3 months.


Dexamethasone, Macular edema, Retinal vein occlusion

Full Text:



Jaulim A, Ahmed B, Khanam T, Chatziralli I. Branch retinal vein occlusion. Retina. 2013;33(5):901-10.

Mitchell P. Prevalence and associations of retinal vein occlusion in Australia. Arch Ophthalmol. 1996;114(10):1243.

Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the beaver dam study. Trans Am Ophthalmol Soc. 2000;98:133-43.

Wong T, Scott I. Retinal-vein occlusion. N Engl J Med. 2010;363(22):2135-44.

Prajapati VA, Vasavada D, Patel SM, Chauhan W, Prajapati V. A study of evaluation of various risk factors of retinal vein occlusion. Int J Res Med Sci. 2014;2(3):1054-7.

Oztas Z, Akkin C, Nalcaci S, Ilim O, Afrashi F. Branch retinal vein occlusion: the importance of the topographical distribution of retinal vessels among risk factors. Eye. 2017;31(5):726-31.

Sahin A, Sahin M, Yüksel H, Türkcü FM, Cınar Y, Cingü AK, et al. The mean platelet volume in patients with retinal vein occlusion. J Ophthalmol. 2013;2013:1-4.

Hamid S, Mirza SA. Anatomic pattern of arteriovenous crossings in BRVO. J Pak Med Assoc. 2008;58(5):233-6.

Wong TY, Larsen EK, Klein R, Mitchell P, Couper DJ, Klein BE, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the atherosclerosis risk in communities and cardiovascular health studies. Ophthalmology. 2005;112(4):540-7.

Rogers S, Mcintosh RL, Lim L, Mitchell P, Cheung N, Kowalsky JW, et al. Natural history of BRVO: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094-101.

Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: The Beaver Dam Eye Study. Arch Ophthalmol. 2008;126(4):513-8.

Haller JA, Bandello F, Belfort R, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):2453-60.

Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124-33.

Haller JA, Bandello F, Belfort JR, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118(12):594-602.

Maggio E, Polito A, Guerriero M, Pertile G. Intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion: 12-month follow-up and prognostic factors. Ophthalmologica. 2014;232(4):207-15.

Chang LJ, Attar M, Acheampong AA. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80-6.

Baptiste D, Lam W, Albiani D, Yoganathan P, Chen J, Kherani A, et al. Real-world assessment of intravitreal dexamethasone implant (0.7 mg) in patients with macular edema: the CHROME study. Clinic Ophthalmol. 2015;9:1255-68.

Kuppermann B, Haller J, Bandello F, Loewenstein A, Jiao J, Li X, et al. Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina. 2014;34(9):1743-9.

Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye. 2012;27(1):65-71.

Alshahrani S, Dolz-Marco R, Gallego-Pinazo R, Diaz-Llopis M, Arevalo J. Intravitreal dexamethasone implant for the treatment of refractory macular edema in retinal vascular diseases. Retina. 2016;36(1):131-6.

Unsal E, Eltutar K, Sultan P, Gungel H. The efficiency of intravitreal dexamethasone implants in the treatment of macular edema secondary to retinal vein occlusion. J Ocul Pharmacol Ther. 2015;31(6):350-6.

Augustin A, Holz F, Haritoglou C, Mayer W, Bopp S, Scheuerle A, et al. Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7 mg for macular oedema secondary to retinal vein occlusion. Ophthalmologica. 2014;233(1):18-26.

Lee E, Han J, Hyon J, Yu H. Changes in choroidal thickness after intravitreal dexamethasone implant injection in retinal vein occlusion. Br J Ophthalmol. 2015;99(11):1543-9.